Navigation Links
CTI Issues Statement Regarding Tosedostat Clinical Trial
Date:6/24/2013

SEATTLE, June 25, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today issued the following statement regarding the notification of the U.S. Food and Drug Administration (the "FDA") partial clinical hold on tosedostat (IND 075503), the Company's aminopeptidase inhibitor under development for the treatment of blood-related cancers, that is being studied in an investigator-sponsored trial and not by CTI. CTI's primary development programs are the ongoing Phase 3 trial of pacritinib, the Company's JAK2/FLT3 inhibitor being evaluated for patients with myelofibrosis, and the post-approval commitment study of PIXUVRI® (pixantrone).

This is a partial clinical hold of only part of the clinical work requested under the investigational new drug ("IND") application. Under a partial clinical hold, although a specific protocol or part of a protocol is not allowed to proceed, other parts of such protocol or other protocols are allowed to proceed under the IND. With this partial clinical hold, the Company may not enter new patients onto any of the ongoing tosedostat protocols until agreement is reached with the FDA.

After a study has been placed on partial clinical hold, the sponsor provides additional information and discusses the adverse event with the FDA to understand whether or not it was associated with the drug or due to another cause. The Company has begun work to comply with the FDA request and expects to be able to submit these data to the FDA in the coming weeks. For additional information, please refer to the Current Report on Form 8-K filed by the Company on June 24, 2013.

Recent Tosedostat Publication
In March 2013, Lancet Oncology published results from the OPAL Phase 2 study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML). The trial showed that once-daily oral tosedostat resulted in a disease contro
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lilly Issues Alert for Illegal Scams Involving Fraudulent Checks and Online Job Requests
2. Celsion Corporation Issues Statement Regarding Misleading Blog Entry
3. Zydus Pharmaceuticals USA Inc. Issues Voluntary Nationwide Recall of Warfarin 2 mg Tablets, Lot MM5767, Expiration Date June 2014, Due to Oversized Tablets
4. Endeavor Power Corporation Issues Corrections on two of its earlier Press Releases dated January 9, 2013 and March 8, 2013
5. Neiman Center Issues Policy Brief Outlining Innovative Health Care Payment Models to Provide Cost-Effective Specialty Care for Patients
6. ISPE Patient Initiative Issues Survey Regarding Patient Experience with Clinical Materials
7. Ampio Pharmaceuticals Issues Statement Regarding Misleading Blog
8. American Academy of Ophthalmology Issues Statement on Provisions to Pharmaceutical Compounding Quality and Accountability Act
9. Royalty Pharma Issues Investor Presentation Highlighting The Strategic And Financial Advantages Of Its Offer To Acquire Elan For $12.50 Per Share In Cash
10. BD Issues 2012 Sustainability Report
11. TNI BioTech, Inc. Corporations CEO Issues Letter to Shareholders Discussing Recent Events
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 2014 Pfenex Inc. (NYSE MKT: PFNX) today announced ... of 8,333,333 shares of its common  stock at a price ... common stock was offered by Pfenex. In addition, Pfenex has ... 1,250,000 additional shares of common stock at the initial public ... the NYSE MKT under the symbol "PFNX." ...
(Date:7/29/2014)... , July 29, 2014  Landauer, Inc. (NYSE: ... and environmental radiation measurement and monitoring, outsourced medical physics ... financial results for the fiscal third quarter 2014 after ... The Company will host a conference call ... a.m. Central Time (10 a.m. Eastern Time). Investors may ...
(Date:7/29/2014)... 29, 2014  Synthetic Biologics, Inc. (NYSE MKT: SYN), ... targeting specific pathogens that cause serious infections and diseases, ... activity in the Company,s stock, the NYSE MKT (the ... usual practice. The Company stated that its policy is ... About Synthetic Biologics, Inc. Synthetic Biologics, Inc. ...
Breaking Medicine Technology:Pfenex Announces Closing of Initial Public Offering 2Landauer, Inc. Sets Date and Time for Announcement of Fiscal Third Quarter 2014 Results 2Synthetic Biologics, Inc. States that Its Policy is Not to Comment on Unusual Market Activity 2
... , MINNETONKA, Minn., Dec. 1 ... company specializing in clinical study management systems, today ... technology solution, has been certified by the Clinical ... the Operational Data Model (ODM) standard. This ...
... , CAMBRIDGE, Mass. and TOKYO, Dec. 1 Galenea ... further extension of their research and development collaboration through ... to seven years and brings the total committed funding ... working together since January 2005 with the goal of ...
Cached Medicine Technology:MedNet Solutions' ENLIGHTEN Receives CDISC ODM Certification 2Galenea and Otsuka Announce Second Extension to Schizophrenia Research Collaboration 2Galenea and Otsuka Announce Second Extension to Schizophrenia Research Collaboration 3
(Date:7/29/2014)... Alan Mozes HealthDay Reporter ... adult autism patients with just a single dose of the ... and emotions, Japanese researchers report. Known as the "love ... emotional bonding between lovers, and between mothers and their children. ... a key area of the brain that has long been ...
(Date:7/29/2014)... 29, 2014 Summer is here, and that means ... a hike, swimming in a pool or laying out on the ... and ticks. The Puppy Store is here to help pet owners ... , It’s almost impossible to completely keep fleas and ticks at ... the chances of their pets coming into contact with fleas and ...
(Date:7/29/2014)... Bret Busacker , a partner ... has been appointed to the Board of Directors for ... is an experienced business attorney with a focus on ... on a wide spectrum of topics regarding equity and ... governance concerns. His clients include public and private businesses, ...
(Date:7/29/2014)... The report, “Heat Transfer Fluids Market by ... Fluids, & Others), by Application (Oil & Gas, Chemical, ... Trends & Forecasts to 2019” defines and segments the ... forecast of the global consumption in terms of volume ... figures spread through 199 page sand in-depth TOC on"Heat ...
(Date:7/29/2014)... (HealthDay News) -- Quitting smoking is harder for people with ... can make it more difficult to ride out the anxiety, ... quit cold turkey, scientists found. But extra exercise -- even ... said. "The review should be seen as a call ... in the department of exercise science at Concordia University in ...
Breaking Medicine News(10 mins):Health News:'Love Hormone' Oxytocin May Help Some With Autism 2Health News:'Love Hormone' Oxytocin May Help Some With Autism 3Health News:Protect Dogs From Fleas and Ticks During the Summer 2Health News:Holland & Hart Partner Brett Busacker Appointed to Board of Directors for American Red Cross of Greater Idaho 2Health News:Heat Transfer Fluids Market Expected to Grow 641,218.19 Tons by 2019 – New Report by MarketsandMarkets 2Health News:Heat Transfer Fluids Market Expected to Grow 641,218.19 Tons by 2019 – New Report by MarketsandMarkets 3Health News:Heat Transfer Fluids Market Expected to Grow 641,218.19 Tons by 2019 – New Report by MarketsandMarkets 4Health News: Extra Exercise Could Help Depressed Smokers Quit: Study 2
... grains and cereals and of magnesium may each be associated ... a report and meta-analysis in the issue of Archives ... of people diagnosed with diabetes worldwide may increase from 171 ... background information in the article. The associated illness, death and ...
... Those men who are facing the surgical removal of ... day will come when they need not worry ... a team of expert urologic surgeons at NewYork-Presbyterian Hospital/Weill ... of reconstructing key anatomical structures that ensure continence. ...
... Maine in Portland have revealed that Depleted Uranium (DU) weapons ... has been denying the possibility. ,Previous research at ... that people exposed to DU dust were at little extra ... inadequately radioactive metal that is used in armour-piercing shells and ...
... shown that subtle signs may enable early prediction of Huntingtons ... and some aspects of personality. ,Dr. Jane ... Lucille A. Carver College of Medicine in Iowa City studied ... ,Each of the participants had at least one parent who ...
... bad tidings for those heavy-handed on multivitamins. The research conducted ... who take more than seven multivitamin tablets a week, can ... type of prostate cancer. ,The researchers who ... Cancer Institute, followed 295,344 men who reported ...
... day could help improve fitness and health of women who ... ,Conducting tests on overweight and obese women, many of whom ... Rouge found that even ten minutes of exercise a day ... their overall risk of early death. ,The study ...
Cached Medicine News:Health News:Risk of Diabetes is Reduced by Intake of Grain Fiber and Magnesium 2Health News:Innovative Procedure Helps Men Minimize Incontinence After Prostatectomy 2Health News:Innovative Procedure Helps Men Minimize Incontinence After Prostatectomy 3Health News:Early Prediction of Huntingtons Disease is Possible by Subtle Signs 2Health News:Being Overzealous With Multivitamins May Lead To Prostate Cancer 2
... Steri-Cath™ Closed Ventilation Suction Systems Reduce ... Constant Patient Ventilation, ,Cost-effective and ... Ventilation Suction Systems reduces the risk ... contact with the catheter, Steri-Cath™ maintains ...
... Catheters are available in two ... DeLee tip with staggered eyes, ... Two types of catheter valve ... easy fingertip control with virtually ...
... Catheters are available in two ... DeLee tip with staggered eyes, ... Two types of catheter valve ... easy fingertip control with virtually ...
... Our Tri-Flo® suction catheter design ... to your patients while still providing ... pediatric catheters (5/6, 8 or 10 ... facilitate proper catheter placement. Our complete ...
Medicine Products: